Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V):

##STR00001##

and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): ##STR00001##
and/or a salt thereof, wherein R.sub.1 is OH or OP(O)(OH).sub.2, and X.sub.1, X.sub.2, X.sub.3, R.sub.2, R.sub.2a, R.sub.a, R.sub.b, and R.sub.c are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P.sub.1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.

The instant invention describes compounds of Formula I having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

##STR00001##

The instant invention describes compounds of Formula I having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

##STR00001##

A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula ##STR00001##
processes for the preparation of such compounds and their use as pharmaceuticals.

A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula ##STR00001##
processes for the preparation of such compounds and their use as pharmaceuticals.

A compound represented by formula (I) ##STR00001## or an N-oxide compound thereof is provided with excellent control efficacies against harmful arthropods, wherein A.sup.1 represents a nitrogen atom or a CR.sup.4; R.sup.4 represents a hydrogen atom, a OR.sup.27, a NR.sup.27R.sup.28, a cyano group, a nitro group, or a halogen atom; ##STR00002##
hereinafter referred to as Het, represents Het-1, Het-2, Het-3, or Het-4: ##STR00003## wherein #.sup.1 represents the binding position of Het and T, and #.sup.2 represents the binding position of Het and ##STR00004## T represents T-1, T-2, T-3, T-4, T-5, T-6, or T-7: ##STR00005## R.sup.1 represents a C1-C10 chain hydrocarbon group having one or more halogen atoms or the like; and R.sup.2 represents a C1-C6 alkyl group optionally having one or more halogen atoms or the like.

A compound represented by formula (I) ##STR00001## or an N-oxide compound thereof is provided with excellent control efficacies against harmful arthropods, wherein A.sup.1 represents a nitrogen atom or a CR.sup.4; R.sup.4 represents a hydrogen atom, a OR.sup.27, a NR.sup.27R.sup.28, a cyano group, a nitro group, or a halogen atom; ##STR00002##
hereinafter referred to as Het, represents Het-1, Het-2, Het-3, or Het-4: ##STR00003## wherein #.sup.1 represents the binding position of Het and T, and #.sup.2 represents the binding position of Het and ##STR00004## T represents T-1, T-2, T-3, T-4, T-5, T-6, or T-7: ##STR00005## R.sup.1 represents a C1-C10 chain hydrocarbon group having one or more halogen atoms or the like; and R.sup.2 represents a C1-C6 alkyl group optionally having one or more halogen atoms or the like.

The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.